News
With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time –– ...
Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...
Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...
Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive ...
23hon MSN
Vertex Pharmaceuticals (Nasdaq: NASDAQ:VRTX) and Ono Pharmaceutical (OTCMKTS: OTCPK:OPHLY) have announced an exclusive ...
22h
Clinical Trials Arena on MSNVertex presents data from Phase I/II stage of trial for type 1 diabetesThe safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.
Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...
Vertex Pharmaceuticals and Ono Pharmaceutical have joined forces to conquer Japan and South Korea with their shiny new weapon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results